Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.

Tina BakerHoda SharifianPaul J NewcombePatrick G GavinMark N LazarusMadhu RamaswamyWendy I WhiteNicola FerrariDaniel MuthasRaj TummalaEric F MorandRichard A FurieEdward M VitalChris ChamberlainAdam PlattHussein Al-MossawiPhilip Z BrohawnEszter Csomor

Published in: Annals of the rheumatic diseases (2024)

Type I IFN blockade with anifrolumab modulated multiple inflammatory pathways downstream of type I IFN signalling, including apoptotic, innate and adaptive mechanisms that play key roles in SLE immunopathogenesis.

Keyphrases

immune response
dendritic cells
gene expression
systemic lupus erythematosus
cell death
dna methylation
oxidative stress
disease activity
anti inflammatory